Financial & Business, OEM News

Senseonics to Obtain Eversense 365 CGM Commercial Operations from Ascensia

The Eversense 365 one-year continuous glucose monitoring system launched in the U.S. in October 2024.

Author Image

By: Sam Brusco

Associate Editor

The Eversense 365 CGM system. Photo: Business Wire

Ascensia Diabetes Care signed a memorandum of understanding to transfer commercial operations for Eversense continuous glucose monitoring (CGM) systems to its maker, Senseonics Holdings. The duo plans to unite Eversense R&D, manufacturing, and commercial activities in Senseonics beginning January 1, 2026.

In collaboration with Senseonics, Ascensia obtained exclusive global distribution rights for Eversense in 2020. It also launched the Eversense 365 one-year CGM system in the U.S. in October 2024.

Eversense said as it grows it market strategy has departed from Ascensia’s core blood glucose monitoring business. The duo, along with Ascensia holding company PHC Holdings (part of PHC Group), agree that unifying development, manufacturing, and distribution to Senseonics would accelerate Eversense’s growth more quickly than under the current structure.

After a definitive agreement is signed, most of Ascensia’s Eversense commercial team will transition to Senseonics, including President of CGM Brian Hansen. PHC Group and Ascensia said they plan to transfer the operations to Senseonics, utilizing Transition Service Agreements as needed, while Senseonics establishes global infrastructure.

“We are very proud to have worked with Senseonics on commercializing Eversense and we are committed to supporting Senseonics in establishing their own commercial operations and smoothly transitioning to them when we have a definitive agreement,” said PHC Group COO and chief strategy officer and CEO of Ascensia, told the press. “PHC Group remains invested in Senseonics and will continue to explore additional growth opportunities in the diabetes space.”

“Eversense is truly differentiated from any other CGM system on the market, and we believe now is the time to bring manufacturing and commercialization together to allow Senseonics to grow and remain responsive to the future needs of people with diabetes,” added Senseonics CEO Tim Goodnow. “We truly appreciate the partnership and investment that PHC Group and Ascensia have made in Senseonics, and we look forward to welcoming the talented commercial team and continuing to build momentum for Eversense 365.”

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters